Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about IORA-RCSTT Coordination Centre on Medicinal Plants Inaugurated at CSIR-CIMAP, Lucknow
The Indian Ocean Rim Association - Regional Centre for Science and Technology Transfer (IORA-RCSTT) Coordination Centre was inaugurated on 7 May 2018 at the Central Institute of Medicinal and Aromatic Plants (CIMAP) campus of the Council of Scientific and Industrial Research (CSIR) in Lucknow.

[adsense:336x280:8701650588]
- Read more about Apotex and Stride joins their Australian business
Strides announced that it has agreed with Apotex, in principle, to merge their respective Australian business operations. The transaction is subject to entering into definitive agreements between the parties, satisfactory due diligence, customary closing conditions and statutory approvals, including approval of Australian Competition and Consumer Commission (ACCC).
- Read more about Does HPV vaccination prevent the development of cervical cancer?
Cochrane Library shows that human papilloma virus (HPV) vaccines protect against cervical lesions in young women, particularly in those who are vaccinated between the ages of 15 and 26. It also summarizes findings on harms that have been assessed in randomized controlled trials.
- Read more about FDA allow marketing of new endoscopic device to treat gastrointestinal bleeding
U.S. Food and Drug Administration permitted marketing of Hemospray, a new device used to help control certain types of bleeding in the gastrointestinal (GI) tract.
- Read more about Scientists found barrier that prevent brain white matter healing
New findings suggest that the molecule triggers a pathway that is normally used by the immune system to prevent excessive damage but may contribute to chronic white matter injury by completely blocking repair operations.
- Read more about ICMR Issue latest guidelines for management of type 2 diabetes
The International Diabetes Federation (IDF) estimates that there are 72.9 million
people with diabetes in India in 2017, which is projected to rise to 134.3 million by the
year 2045. The prevalence of diabetes in urban India, especially in large metropolitan
cities has increased from 2% in the 1970s to over 20% at present and the rural areas
are also fast catching up.
- Read more about FDA approves uses of Tafinlar (dabrafenib) and Mekinist (trametinib) in combination
The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive).
- Read more about Central Government strengthens TB cure by making obligatory action from doctors and pharmacists to submit complete info on tuberculosis patients
Government takes obligatory action for collecting data of all tuberculosis patients to ensure proper tuberculosis diagnosis and its management in patients and their contacts and to reduce tuberculosis transmission and further to address the problems of emergence and spread of Drug Resistant-Tuberculosis.
- Read more about Air pollution levels remain dangerously high in many parts of the world
New data from WHO shows that 9 out of 10 people breathe air containing high levels of pollutants. Updated estimations reveal an alarming death toll of 7 million people every year caused by ambient (outdoor) and household air pollution.
- Read more about Regeneron and Sanofi to reduce price of their Cardiovascular Medicine
Regeneron Pharmaceuticals, Inc. and Sanofi announced they will lower the net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access from Express Scripts. Praluent will become the exclusive PCSK9 inhibitor therapy on the Express Scripts national formulary. The agreement significantly simplifies the documentation necessary to secure insurance coverage and may help reduce out-of-pocket costs for eligible patients. Despite having the broadest U.S. formulary coverage of any PCSK9 inhibitor, many patients have been unable to access Praluent because of the complicated utilization management process required by some insurance companies and high patient out-of-pocket costs.